Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 55 of 5804
-
New drug combo aims to slow advanced lung cancer in patients with EGFR mutations
Disease control OngoingThe aim of the study is to evaluate the efficacy and safety of SKB264 in combination with osimertinib as first-Line treatment for patients with epidermal growth factor receptor (EGFR) mutations, locally advanced or metastatic non-squamous non-small cell lung cancer.
Phase: PHASE3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Engineered immune cells take on tough blood cancers
Disease control CompletedThis study is testing a new type of treatment called anti-CD19 CAR-T cell therapy for adults with certain blood cancers that have returned or did not respond to previous treatments. CAR-T cells are a type of immune cell that is specially designed in a lab to target and destroy ca…
Phase: PHASE1, PHASE2 • Sponsor: National Research Center for Hematology, Russia • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Race against time: can quick valve surgery save shock patients?
Disease control Recruiting nowThe goal of this clinical trial is to learn if acute transcatheter aortic valve implantation (TAVI) is superior to standard treatment (stabilization in an intensive care unit and TAVI subsequently) to treat cardiogenic shock in patients with critical severe aortic stenosis. The …
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take on tough autoimmune diseases
Disease control Recruiting nowThe goal of this study is to evaluate the safety and effi cacy of CD19 CAR T cells in the treatment of Refractory Autoimmune Diseases.
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug cocktail aims to tackle tough stomach cancer
Disease control Recruiting nowThis is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positive locally advanced/metastatic adenocarci…
Phase: PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New pill shows promise against tough lung cancer mutations
Disease control Recruiting nowThis study is a randomized, open, multicenter phase III clinical study, which aims to evaluate the efficacy and safety of firmonertinib mesylate compared with platinum based chemotherapy for patients with locally advanced or metastatic NSCLC who have not been treated with systemi…
Phase: PHASE3 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
A One-Shot gene therapy could take on incurable blood cancer
⭐️ CURE ⭐️ TerminatedThis is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of ESO-T01 for patients with relapsed/refractory multiple myeloma.
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
One shot for two viruses: new combo vaccine tested in seniors
⭐️ VACCINE ⭐️ CompletedThe purpose of the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea).
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:00 UTC
-
Can a new RSV vaccine keep adults out of the hospital? 690,000 join trial
⭐️ VACCINE ⭐️ OngoingThe purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of bivalent RSV prefusion F vaccine (RSV vaccine) in adults. Participants will be randomized 1:1 to either RSV vaccine or no RSV vaccine.
Phase: PHASE4 • Sponsor: Tor Biering-Sørensen • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
-
New drug rilvegostomig takes on keytruda in lung cancer showdown
Disease control Recruiting nowThe purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Can a cancer drug stop leukemia before it starts?
Prevention Recruiting nowThe purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with the HTLV-1 virus and because of…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 09:11 UTC
-
New nanobody CAR t therapy targets tough leukemia
Disease control Recruiting nowTo evaluate the efficacy and safety of Nanobody-Based CD19/CD22 Tandem Dual Chimeric Antigen Receptor (CAR) T-cell therapy in patients with relapsed or refractory B-ALL
Phase: PHASE1, PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Can a targeted pill shrink a rare, Treatment-Resistant stomach cancer?
Disease control Recruiting nowAn international multicenter, open, single-arm pivotal registration phase III study to determine the efficacy and safety of olverembatinib in patients with SDH-deficient gastrointestinal stromal tumor (GIST) who have previously been treated with one-line therapy, and to evaluate …
Phase: PHASE3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug could prevent eye cancer recurrence in High-Risk patients
Disease control Recruiting nowAt least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in pa…
Phase: PHASE3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for rare leukemia: phase 3 trial of IMM01 combo launches
Disease control Recruiting nowThis study is a randomized, controlled, double-blind, multicenter, phase Ⅲ clinical study to evaluate the efficacy of IMM01(timdarpacept) in combination with azacitidine versus placebo in combination with azacitidine in patients with newly diagnosed chronic leukemia monocytic (CM…
Phase: PHASE3 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New hope for kids with relapsed neuroblastoma: BEACON2 trial tests drug cocktails
Disease control Recruiting nowNeuroblastoma is one of the most common solid childhood tumours, and a major cause of cancer-related death in children. More than 1200 children/young adults a year are diagnosed in USA and Europe. Around 600 of these cases are considered high-risk, which means the cancer is more …
Phase: PHASE1, PHASE2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Could antibody shots replace daily HIV pills for kids? new trial begins in botswana
Disease control Recruiting nowThe purpose of this study is to advance pediatric HIV treatment and cure research by evaluating the impact of a combination of three anti-HIV-1 broadly neutralizing antibodies (bNAbs) or analytic treatment interruption (ATI) on viral reservoir, immune function, and maintenance of…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could cheaper scans replace MRI for women with dense breasts?
Diagnosis Recruiting nowWomen with extremely dense breasts (nearly all glandular and connective tissue, little fatty tissue) have a 3-6 times higher risk of breast cancer than women with very low breast density. Moreover, due to the masking effect of the dense tissue, any breast tumours present are more…
Phase: NA • Sponsor: C.H. van Gils • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
Two-Drug combo aims to cure chronic hepatitis b
Disease control OngoingThe study is intended to evaluate the efficacy and safety of 2 different doses of DAP/TOM followed by bepirovirsen in participants living with CHB on standard of care nucleos(t)ide analogue (NA) therapy. The study also aims to identify an optimal dose of DAP/TOM for sequenced the…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug aims to prevent deadly bleeding in unborn babies
Disease control Recruiting nowThe purpose of this study is to evaluate the effectiveness of nipocalimab compared with placebo in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC